Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation

scientific article published on 01 October 1997

Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0003-4975(97)00845-X
P698PubMed publication ID9354506

P2093author name stringS Gupta
L Baker
M S Mulligan
J P Lynch
F J Martinez
R I Whyte
S J Rossi
R Florn
P2860cites workObliterative bronchiolitis after lung and heart-lung transplantationQ41096367
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantationQ45039146
RS-61443--a new, potent immunosuppressive agentQ45300416
Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trialsQ48786548
Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.Q51048799
Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantationQ71023240
Aerosolized cyclosporine in lung recipients with refractory chronic rejectionQ71046268
Clinical trial of tacrolimus versus cyclosporine in lung transplantationQ71710715
Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and managementQ71873465
Bronchiolitis obliterans in single-lung transplant recipientsQ72129884
Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetilQ72854731
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectbronchiolitisQ424227
lung transplantQ1637912
P304page(s)945-948
P577publication date1997-10-01
P1433published inThe Annals of Thoracic SurgeryQ1939819
P1476titleMycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation
P478volume64

Reverse relations

cites work (P2860)
Q37902258A review of bronchiolitis obliterans syndrome and therapeutic strategies
Q35625678Bronchiolitis obliterans
Q36623201Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation
Q44893166Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients
Q53344804Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment.
Q46421609Esophageal Motor Dysfunction and Gastroesophageal Reflux Are Prevalent in Lung Transplant Candidates
Q33996931Immunosuppression for lung transplantation
Q38240865Immunosuppression in lung transplantation
Q34538559Immunosuppression in transplantation. A new millennium in care.
Q94476118Immunosuppressive strategies in lung transplantation
Q55385759Individualizing immunosuppression in lung transplantation.
Q74842942Lung retransplantation in children
Q34395027Lung transplantation for primary pulmonary hypertension
Q35293950Lung transplantation. Bronchiolitis obliterans syndrome
Q35214723Lung transplants with tacrolimus and mycophenolate mofetil: a review
Q39033218Observational Study of Methotrexate in the Treatment of Bronchiolitis Obliterans Syndrome.
Q34533624Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
Q33957200The use of mycophenolate mofetil in transplant recipients
Q44280627Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome
Q35711255Use of cyclosporine in thoracic transplantation

Search more.